Press Release
Hybrigenics updates its web communication
Hybrigenics launches a new website dedicated to its Services subsidiary and a new version of its corporate website
Paris, 05 September 2012 - Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases, today announces the launch of a new website dedicated to Hybrigenics Services, its subsidiary specialised in protein interaction research, and of a new version of its corporate website.
Hybrigenics Services' website (www.hybrigenics-services.com) has been specifically designed to get optimal scientific and commercial impact on its main customer base: researchers in life sciences from all around the world. The new version of Hybrigenics' corporate website (www.hybrigenics.com) is targeting its investor base and potential pharmaceutical partners. Both websites emphasize user-friendliness, clarity and proximity.
"We invite our shareholders and anyone with an interest in Hybrigenics to visit our web sites and let us know their feed-back through the contact page," said Remi Delansorne, Hybrigenics' CEO.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical
company listed (ALHYG) on Alternext (NYSE- Euronext) in
Paris, focusing its internal R&D programs on innovative
targets and therapies for the
treatment of proliferative cancerous or non-cancerous
diseases.
Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has recently been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is about to be tested in chronic lymphocytic leukemia patients.
Hybrigenics has a research collaboration with Servier on
deubiquitinating enzymes and their inhibitors in oncology,
neurology, psychiatry, rheumatology, ophthalmology, diabetes
and cardiovascular diseases. Hybrigenics continues to build
on its pioneer research position in the field of
ubiquitin-specific proteases by exploring their role in other
areas of particular relevance, such as inflammation and
virology.
Hybrigenics Services (www.hybrigenics-services.com), a
fully-owned subsidiary, is the market leader in Yeast
Two-Hybrid (Y2H) and related services to identify, validate
and inhibit protein interactions for researchers in all areas
of life sciences, using its ISO 9001-certified
high-throughput Y2H screening platform, its sophisticated
bioinformatics tools and extensive database, along with its
chemical library and chemical screening platform.
***
HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG
Hybrigenics Rémi Delansorne CEO
Tel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com
NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.fr
1/1
distributed by |